Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16185304 | 0.90 | MAOB (0.35) | MAOBGRM2KCNH2P2RX7FSCN1 | |
| SCHEMBL16185259 | 0.83 | GRM2 (0.36) | GRM2KCNH2P2RX7FSCN1MCL1 | |
| SCHEMBL4749017 | 0.77 | KCNH2 (0.44) | GRM2KCNH2 | |
| SCHEMBL3907766 | 0.75 | ERCC1 (0.44) | GRM2KCNH2P2RX7ERCC1ERCC4 | |
| SCHEMBL2895650 | 0.75 | MAOB (0.38) | MAOBGRM2KCNH2P2RX7ERCC1 | |
| SCHEMBL4746426 | 0.75 | FSCN1 (0.39) | P2RX7FSCN1 | |
| SCHEMBL16185299 | 0.74 | ERCC1 (0.36) | MAOBGRM2KCNH2ERCC1ERCC4 | |
| SCHEMBL17537021 | 0.74 | ERCC1 (0.36) | MAOBGRM2KCNH2ERCC1ERCC4 | |
| SCHEMBL16185260 | 0.74 | ERCC1 (0.36) | MAOBGRM2KCNH2ERCC1ERCC4 | |
| SCHEMBL4743344 | 0.73 | CLPP (0.39) | MAOBGRM2KCNH2ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986291-B1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-27 | — | — | EP | claimed |
| EP-2986291-B1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-2986291-B1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-27 | — | — | EP | disclosed |
| US-9493479-B2 | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493479-B2 | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493479-B2 | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2014172188-A2 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060272-A1 | 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS | PNPO, TYMP, PDXK | MAOB 387/4885GRM2 4171/4885KCNH2 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.